A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women
- 31 May 1999
- journal article
- clinical trial
- Published by Elsevier BV in Bone
- Vol. 24 (5), 517-523
- https://doi.org/10.1016/s8756-3282(99)00076-9
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Apparent Pre- and Postmenopausal Bone Loss Evaluated by DXA at Different Skeletal Sites in Women: The OFELY CohortJournal of Bone and Mineral Research, 1997
- Hormone replacement therapy in the prevention and treatment of osteoporosisOsteoporosis International, 1997
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective studyJournal of Bone and Mineral Research, 1996
- Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacyBone, 1996
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosisJournal of Bone and Mineral Research, 1996
- Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal agesClinical Endocrinology, 1996
- The worldwide problem of osteoporosis: Insights afforded by epidemiologyBone, 1995
- Transdermal EstradiolDrugs, 1990
- Preventive effects of transdermal administration of 17|3-estradiol on postmenopausal bone loss: A 2-year prospective studyGynecological Endocrinology, 1989
- LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN: EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENTThe Lancet, 1976